1. ¹Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, New South Wales 2010, Australia
2. ²Department of Anatomical Pathology, Royal Prince Alfred Hospital, Missenden Road, Camperdown, Sydney, New South Wales 2050, Australia
3. ³Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, New South Wales 2145, Australia
4. ⁴The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3050, Australia
5. ⁵Department of Pathology, University of Sydney, New South Wales 2006, Australia
6. ⁶Division of Surgery, Bankstown Hospital, Eldridge Road, Bankstown, Sydney, New South Wales 2200, Australia

Correspondence: Dr AV Biankin, Pancreatic Cancer Research Group, Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, New South Wales 2010, Australia. E-mail: a.biankin@garvan.org.au

Received 8 June 2007; Revised 30 October 2007; Accepted 5 December 2007; Published online 29 January 2008.

Abstract

Identification of a biomarker of prognosis and response to therapy that can be assessed preoperatively would significantly improve overall outcomes for patients with pancreatic cancer. In this study, patients whose tumours exhibited high LMO4 expression had a significant survival advantage following operative resection, whereas the survival of those patients whose tumours had low or no LMO4 expression was not significantly different when resection was compared with operative biopsy alone.